SARS-CoV-2 N protein exerts antitumor effects in NSCLC by inducing DNA damage and augmenting chemotherapeutic sensitivity.

Publication date: Jun 01, 2025

Recently, we reported that the SARS-CoV-2 nucleocapsid (N) protein triggers DNA damage by inducing autophagic degradation of RNAi components (Dicer and XPO5) and splicing factors (SRSF3 and hnRNPA3). In this study, we found that the SARS-CoV-2 N protein synergizes with chemotherapeutics to induce DNA damage and activate the cGAS-STING pathway in NSCLC cells. Moreover, the SARS-CoV-2 N protein acts synergistically with chemotherapeutics to suppress the proliferation and colony formation of NSCLC cells. Finally, we demonstrated that the SARS-CoV-2 N protein enhances the antitumor effects of etoposide in xenograft tumor mouse model. These findings reveal a novel antitumor mechanism of the SARS-CoV-2 N protein, positioning it as a potential therapeutic agent for lung cancer patients.

Concepts Keywords
Antitumor Animals
Hnrnpa3 Antineoplastic Agents
Model Antineoplastic Agents
Splicing Cancer
Tumor Carcinoma, Non-Small-Cell Lung
Cell Line, Tumor
Cell Proliferation
cGAS-STING
Coronavirus Nucleocapsid Proteins
Coronavirus Nucleocapsid Proteins
COVID-19
COVID-19
DNA Damage
DNA damage
Etoposide
Etoposide
Humans
Lung Neoplasms
Mice
Mice, Nude
nucleocapsid phosphoprotein, SARS-CoV-2
Phosphoproteins
Phosphoproteins
SARS-CoV-2
SARS-CoV-2 nucleocapsid protein

Semantics

Type Source Name
disease IDO protein
disease MESH DNA damage
disease IDO colony
drug DRUGBANK Etoposide
disease MESH tumor
disease MESH lung cancer
disease MESH Carcinoma Non-Small-Cell Lung
disease IDO cell
disease MESH COVID-19

(Visited 1 times, 1 visits today)